Ibrutinib in Combination With Lenalidomide and Rituximab in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Inclusion Criteria

• Pathologically confirmed relapsed/ refractory DLBCL
• Must have previously received first line treatment regimen
• Must be ineligible for high dose therapy/ stem cell transplantation
• Measurable disease sites on computed tomography (CT) scan (>1.5 cm in longest dimension)
• prothrombin time/international normalized ratio (PT/INR) < 1.5 x upper limit of normal (ULN) and partial thromboplastin time (PTT; activated partial thromboplastin time [aPTT]) <1.5 x ULN
• Men and women ≥18 years of age
• Eastern Cooperative Oncology Group (ECOG) < 2
• Adequate hepatic and renal function
• Adequate hematologic function

Exclusion Criteria

• Medically apparent central nervous system lymphoma or leptomeningeal disease
• History of allogeneic stem-cell (or other organ) transplantation
• Any chemotherapy, external beam radiation therapy, or anticancer antibodies within 2 weeks
• Radio- or toxin-immunoconjugates within 10 weeks
• Concurrent enrollment in another therapeutic investigational study or have previously taken ibrutinib and/or lenalidomide.